Condition: Transfusion Dependent Beta-Thalassemia · Sponsor: First Affiliated Hospital of Guangxi Medical University
This is a single-arm, open label, single-dose study in subjects with transfusion dependent β-thalassaemia. The study will evaluate the safety and efficacy of autologous CD34+ Human Hematopoietic Stem Cells that was transduced with LentiRed Lentivrial vector.
This description comes directly from the study's public registry record.
Yongrong Lai, PhD · 86-771-5356746 · laiyongrong@hotmail.com
Always discuss trial participation with your own doctor first.
| The affiliated hospital of guangxi medical university | Nanning, Guangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05762510